| B cell Phenotype (cells/μL) |
CFS Patients |
Non-fatigued controls |
P-value |
| Naive |
86.62 ± 21.14 |
113.81 ± 23.05 |
0.43 |
| T1/2 |
10.61 ± 2.75 |
16.45 ± 3.52 |
0.56 |
| Maturenaive |
11.42 ± 2.75 |
14.85 ± 5.23 |
0.42 |
| T3 |
59.24 ± 15.22 |
72.29 ± 16.05 |
0.51 |
| Non-switched |
4.85 ± 2.30 |
4.03 ± 2.53 |
0.53 |
| Doublenegative |
223.31 ± 30.78 |
236.72 ± 29.78 |
0.44 |
| switched |
137.37 ± 12.97 |
113.21 ± 14.73 |
0.47 |
| Plasmablast |
96.66 ± 9.03 |
88.56 ± 11.05 |
0.49 |
| HLA-DRplasma cells |
90.61 ± 8.46 |
78.45 ± 9.79 |
0.52 |
| Plasmacells |
1.45 ± 0.23 |
1.84 ± 1.9 |
0.61 |
| |
| B cell Receptors (%) |
CFS Patients |
Non-fatigued controls |
P-value |
| Total CD79α+β+ (BCR) |
58.99 ± 4.46 |
58.72 ± 5.92 |
0.74 |
| CD40L+ |
4.01 ± 0.60 |
4.68 ± 1.23 |
0.65 |
| BCR IgE+ |
3.05 ± 1.30 |
2.62 ± 1.87 |
0.9 |
| BCR IgA+ |
54.02 ± 4.02 |
50.47 ± 5.24 |
0.83 |
| BCR IgD+ |
7.24 ± 3.21 |
9.76 ± 3.24 |
0.48 |
| *CD - Cluster of Differentiation, Ig – Immunoglobulin; HLA – Human Leucocyte Antigen; T1/2 – transitional 1 and 2; T3 – transitional 3, BCR – B cell receptor complex. |
|
